论文部分内容阅读
目的观察培美曲塞联合卡铂在鼻咽癌二线治疗中的临床疗效和不良反应。方法培美曲塞500 mg/m2,第1天;卡铂,AUC5,第1天,21 d为1个周期。所有病例均接受至少2个周期的化疗。结果 14例患者入组,均可评价疗效,CR 1例,PR 3例,RR为28.6%(4/14),SD为35.7%(5/14),PD为35.7%(5/14)。中位随访时间6个月,中位TTP 3.5个月,1年生存率为35.7%。主要不良反应为骨髓毒性、疲乏,3例(21.4%,3/14)发生了Ⅲ~Ⅳ度白细胞减少;2例(14.3%,2/14)发生了Ⅲ度血小板减少;2例(14.3%,2/14)发生了Ⅲ度疲乏。结论培美曲塞联合卡铂方案二线治疗复发或转移性鼻咽癌有较好的疗效,患者耐受性好,值得临床进一步研究。
Objective To observe the clinical efficacy and adverse reactions of pemetrexed combined with carboplatin in second-line treatment of nasopharyngeal carcinoma. Methods pemetrexed 500 mg / m2 on day 1; carboplatin, AUC5, on day 1, 21 d for a cycle. All cases received at least 2 cycles of chemotherapy. Results All the 14 patients were enrolled in the study. CR was 1 case and PR was 3 cases. RR was 28.6% (4/14), SD was 35.7% (5/14) and PD was 35.7% (5/14). The median follow-up time was 6 months. The median TTP was 3.5 months and the 1-year survival rate was 35.7%. The main adverse reactions were myelotoxicity and fatigue. Ⅲ ~ Ⅳ leukopenia occurred in 3 cases (21.4%, 3/14), Ⅲ degree thrombocytopenia occurred in 2 cases (14.3%, 2/14), and thrombocytopenia in 2 cases (14.3% , 2/14) Ⅲ degree of fatigue occurred. Conclusion pemetrexed combined with carboplatin regimen second-line treatment of recurrent or metastatic nasopharyngeal carcinoma has a good effect, patients with good tolerance, it is worth further clinical study.